You are here
In the early 2010’s, The National Institute of Integrative Medicine undertook a clinical trial into Sono-photodynamic therapy and a study on New Generation PDT light delivery technology.
Photodynamic therapy (PDT) utilises a specific laser frequency and attempts to damage or destroy cancer cells. The cancer cells are primed with a photosensitising drug to react to the laser wavelength frequency, while normal cells in the surrounding environment remain un-reactive and unharmed.
Please be aware that the Photodynamic Therapy has ENDED NIIM is not accepting participants for either of these research projects.
New Generation Photodynamic Therapy (NGPDT)
PDT as a method of cancer treatment has been used exclusively in the treatment of superficial tumours due to the limitations of the laser light to penetrate into deep tissues.
The NIIM NGPDT clinical trial investigated the efficacy of New Generation PDT light delivery technology in conjunction with a newly developed photosensitising agent in penetrating to cancers of deep tissues. The trial concluded in 2012 and results were published in 2013, you can view the published results at f1000 Research here.
Sono-PDT for Prostate Cancer
Sono-photodynamic therapy (SPDT) utilises both sound and light frequencies to damage and destroy tumors. A sensitising agent primes the tumor cells to specific frequencies, but has no effect on regular, healthy cells.
Administration of SPDT through localised and whole body routes then causes a reaction within the sensitised tumor cells, which results in formation of reactive oxygen species (ROS), destroying the tumor mass. The therapy produces minimal side effects and does not damage surrounding tissues. The SPDT clinical trial treated men with prostate cancer who had not responded to previous treatment. The trial concluded in 2012 and results were published in 2013, you can view the published results at f1000 Research here.